

Table I. Clinicopathological characteristics of patients with and without lymphocyte-predominant breast cancer (LPBC).

Characteristic		LPBC (n=18)	Non-LPBC (n=57)	<i>p</i> -Value
Age, years	Mean±SD	51.4±11.8	52.1±9.6	
Clinical T-stage, n (%)	T1	1 (5.6)	8 (14.0)	0.63
	T2	12 (66.7)	31 (54.4)	
	T3	2 (11.1)	6 (10.5)	
	T4	3 (16.6)	12 (21.1)	
Clinical N-stage, n (%)	Negative	9 (50.0)	23 (40.4)	0.31
	Positive	9 (50.0)	34 (59.6)	
Nuclear grade, n (%)	1	1 (5.6)	3 (5.3)	0.24
	2	3 (16.6)	17 (29.8)	
	3	14 (77.8)	37 (64.9)	
Ki67, n (%)	<20%	1 (5.6)	7 (12.3)	0.38
	≥20%	17 (94.4)	50 (87.7)	
ER, n (%)	ER+	8 (44.4)	39 (68.4)	0.03
	ER-	10 (55.6)	18 (31.6)	
HER2, n (%)	HER2+	8 (44.4)	21 (36.8)	0.72
	HER2-	10 (55.6)	36 (63.2)	
Subtype, n (%)	ER+, HER2-	3 (16.7)	23 (40.3)	0.06
	ER+, HER2+	6 (33.3)	16 (28.1)	
	ER-, HER2+	2 (11.1)	5 (8.8)	
	Triple-negative	7 (38.9)	13 (22.8)	

ER: Estrogen receptor; HER2: human epidermal growth factor receptor 2; triple-negative: negative for ER, progesterone receptor, and HER2. Statistically significant *p*-values are shown in bold.